Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 1

Conditions

Neoplasms 3Skin Carcinoma 1Patient Satisfaction 1Hematologic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Aftercare × Clear all
NCT03943082 2021-11-16

Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

University of California, San Francisco

Phase NA Terminated
252 enrolled
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT02637349 2019-11-26

POST

Polaris Health Directions

Phase 2 Completed
200 enrolled
Tumor-Agnostic

Neoplasms

NCT02440737 2019-10-18

NEST

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
67 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡